- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cyclacel Pharmaceuticals Inc.
Headquarters: Berkeley Heights, NJ, United States
Website: https://cyclacel.com/
Year Founded: 1996
Status: Public
Industry Sector: HealthTechnology
CEO: Sing Ee Wong, DBA
Number Of Employees: N/A
Enterprise Value: $-1,123,377
PE Ratio: -0.04
Exchange/Ticker 1: NASDAQ:CYCC
Exchange/Ticker 2: N/A
Latest Market Cap: $1,279,325,184
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
BioCentury | Aug 28, 2020
Emerging Company Profile
Concarlo: targeting proliferation and resistance in one go
SUNY Downstate spinout takes aim at metastatic breast cancer by targeting p27
BioCentury | Apr 21, 2020
Product Development
Trio of tactics to target COVID-19 hyperinflammation
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Aug 17, 2017
Clinical News
Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors
BioCentury | Sep 29, 2016
Distillery Therapeutics
Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)
Items per page:
1 - 10 of 145